{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:33:49Z","timestamp":1760524429364,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["IGA_LF_2022_001"],"award-info":[{"award-number":["IGA_LF_2022_001"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MZ \u010cR \u2013 RVO (FNOL","00098892)"],"award-info":[{"award-number":["MZ \u010cR \u2013 RVO (FNOL","00098892)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV NU21-03-00386"],"award-info":[{"award-number":["AZV NU21-03-00386"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007672","name":"L\u00e9ka\u0159sk\u00e1 Fakulta v Plzni, Univerzita Karlova","doi-asserted-by":"publisher","award":["UNCE 204021"],"award-info":[{"award-number":["UNCE 204021"]}],"id":[{"id":"10.13039\/100007672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019214","name":"l\u00e9ka\u0159sk\u00e1 fakulta Univerzity Karlovy","doi-asserted-by":"publisher","award":["EXCELES","PROGRES Q40\/08"],"award-info":[{"award-number":["EXCELES","PROGRES Q40\/08"]}],"id":[{"id":"10.13039\/100019214","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib revolutionized therapy for relapsed\/refractory (R\/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R\/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of 14.0\u00a0months, 56 patients relapsed\/progressed, and 45 died. The overall response rate was 66%, with 31% of complete metabolic remissions on PET\/CT. The median progression-free and overall survival (OS) rates were 10.3 and 23.1\u00a0months, respectively. The median OS from ibrutinib failure was 3.7\u00a0months. High proliferation rate by Ki67 (\u2265\u200930%) and two or more previous therapy lines both negatively correlated with outcome (HR\u2009=\u20092.2, <jats:italic>p<\/jats:italic>\u2009=\u20090.04, and HR\u2009=\u20092.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.08, respectively). Female gender borderline correlated with better outcome (HR\u2009=\u20090.53, <jats:italic>p<\/jats:italic>\u2009=\u20090.08). In multivariate analysis, Ki67 and response to ibrutinib both correlated with OS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Importantly, ibrutinib appeared to better control nodal and extranodal lymphoma than bone marrow (BM) involvement. From 20 patients with detectable BM infiltration (before ibrutinib initiation) achieving complete (<jats:italic>n<\/jats:italic>\u2009=\u200913) or partial (<jats:italic>n<\/jats:italic>\u2009=\u20097) metabolic remission, none achieved remission in BM. We confirmed good efficacy of ibrutinib in unselected heavily pre-treated MCL patients. Our findings support the use of a combination of ibrutinib and rituximab in patients with BM involvement.<\/jats:p>","DOI":"10.1007\/s00277-022-05023-2","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T23:02:43Z","timestamp":1668207763000},"page":"107-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3074","authenticated-orcid":false,"given":"Ales","family":"Obr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Janikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Mocikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hruskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Vockova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Salek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Sykorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Malarikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Papajik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"5023_CR1","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S et al (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv62-71","journal-title":"Ann Oncol"},{"key":"5023_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. JCO 27:511\u2013518","journal-title":"JCO"},{"key":"5023_CR3","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677\u20132684","journal-title":"Blood"},{"key":"5023_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","volume":"6","author":"E Zucca","year":"1995","unstructured":"Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A et al (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257\u2013262","journal-title":"Ann Oncol"},{"key":"5023_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3109\/10428194.2013.815349","volume":"55","author":"D Salek","year":"2014","unstructured":"Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S et al (2014) Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymph 55:802\u2013810","journal-title":"Leuk Lymph"},{"key":"5023_CR6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/leu.2012.72","volume":"26","author":"C Royo","year":"2012","unstructured":"Royo C, Navarro A, Clot G, Salaverria I, Gin\u00e9 E, Jares P et al (2012) Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 26:1895\u20131898","journal-title":"Leukemia"},{"key":"5023_CR7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558\u2013565","journal-title":"Blood"},{"key":"5023_CR8","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A et al (2014) Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. JCO 32:1338\u20131346","journal-title":"JCO"},{"key":"5023_CR9","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd H-W, Hartmann S, Loddenkemper C et al (2016) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. JCO 34:1386\u20131394","journal-title":"JCO"},{"key":"5023_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"M-H Delfau-Larue","year":"2015","unstructured":"Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G et al (2015) High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 126:604\u2013611","journal-title":"Blood"},{"key":"5023_CR11","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB et al (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130:1903\u20131910","journal-title":"Blood"},{"key":"5023_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue M-H, Rymkiewicz G et al (2018) Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 131:417\u2013420","journal-title":"Blood"},{"key":"5023_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","volume":"18","author":"A Obr","year":"2018","unstructured":"Obr A, Proch\u00e1zka V, Jirkuvov\u00e1 A, Urb\u00e1nkov\u00e1 H, Kriegova E, Schneiderov\u00e1 P et al (2018) TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 18:762\u2013768","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"5023_CR14","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1111\/bjh.17063","volume":"191","author":"A Obr","year":"2020","unstructured":"Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H et al (2020) A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 191(5):e103\u2013e106. https:\/\/doi.org\/10.1111\/bjh.17063","journal-title":"Br J Haematol"},{"key":"5023_CR15","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/cancers12082120","volume":"12","author":"D Malarikova","year":"2020","unstructured":"Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K et al (2020) Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers 12:2120","journal-title":"Cancers"},{"key":"5023_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520\u2013531","journal-title":"N Engl J Med"},{"key":"5023_CR17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C et al (2017) Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 377:1250\u20131260","journal-title":"N Engl J Med"},{"key":"5023_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1080\/10428194.2018.1508672","volume":"60","author":"A Obr","year":"2019","unstructured":"Obr A, Prochazka V, Papajik T, Klener P, Janikova A, Salek D et al (2019) Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry \u2020. Leuk Lymph 60:748\u2013755","journal-title":"Leuk Lymph"},{"key":"5023_CR19","doi-asserted-by":"crossref","unstructured":"Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, et al (2018) Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol ajh.25362","DOI":"10.1002\/ajh.25362"},{"key":"5023_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/hon.2483","volume":"36","author":"P Klener","year":"2018","unstructured":"Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M et al (2018) Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol 36:110\u2013115","journal-title":"Hematol Oncol"},{"key":"5023_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516","journal-title":"N Engl J Med"},{"key":"5023_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B et al (2017) Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 179:430\u2013438","journal-title":"Br J Haematol"},{"key":"5023_CR23","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B et al (2019) Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 104:e211-4","journal-title":"Haematologica"},{"key":"5023_CR24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2019-124691","volume":"134","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling MH, Goy A, Hess G, Auer R, Kahl BS et al (2019) Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. Blood 134:1538\u20131538","journal-title":"Blood"},{"key":"5023_CR25","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1016\/j.clml.2019.07.294","volume":"19","author":"B Pati\u00f1o-Escobar","year":"2019","unstructured":"Pati\u00f1o-Escobar B, Enciso-Olivera L, Acon-Solano C, Otero-De la Hoz D, Martinez-Cordero H, Spirko P et al (2019) Real world data on the efficacy and safety of ibrutinib in relapsed\/refractory mantle cell lymphoma. Data collected from the Colombian Hematology Centers. Clin Lymphoma Myeloma Leuk 19:S317-8","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5023_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bjh.17363","volume":"193","author":"R McCulloch","year":"2021","unstructured":"McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A et al (2021) Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 193:290\u2013298","journal-title":"Br J Haematol"},{"key":"5023_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/bjh.16739","volume":"192","author":"D Tucker","year":"2021","unstructured":"Tucker D, Morley N, MacLean P, Vandenberghe E, Booth S, Parisi L et al (2021) The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed\/refractory mantle cell lymphoma. Br J Haematol 192:1035\u20131038","journal-title":"Br J Haematol"},{"key":"5023_CR28","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","volume":"8","author":"Y Jeon","year":"2019","unstructured":"Jeon Y, Yoon S, Min GJ, Park S, Park S, Yoon J et al (2019) Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med 8:6860\u20136870","journal-title":"Cancer Med"},{"key":"5023_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS et al (2017) Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study. Hematol Oncol 35:528\u2013535","journal-title":"Hematol Oncol"},{"key":"5023_CR30","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"5023_CR31","first-page":"649","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative. Oncology Group: Am J Clin Oncol 5:649\u2013656","journal-title":"Oncology Group: Am J Clin Oncol"},{"key":"5023_CR32","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO 32:3059\u20133067","journal-title":"JCO"},{"key":"5023_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M et al (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387:770\u2013778","journal-title":"Lancet"},{"key":"5023_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.15411","volume":"182","author":"P Jain","year":"2018","unstructured":"Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J et al (2018) Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL). Br J Haematol 182:404\u2013411","journal-title":"Br J Haematol"},{"key":"5023_CR35","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D\u2019Amore F et al (2014) Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 124:1288\u20131295","journal-title":"Blood"},{"key":"5023_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"5023_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc.2016.30","volume":"16","author":"A Clocchiatti","year":"2016","unstructured":"Clocchiatti A, Cora E, Zhang Y, Dotto GP (2016) Sexual dimorphism in cancer. Nat Rev Cancer 16:330\u2013339","journal-title":"Nat Rev Cancer"},{"key":"5023_CR38","unstructured":"Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, et al (2021) Ibrutinib with rituximab in first-line treatment of older patients With mantle cell lymphoma. JCO JCO.21.01797"},{"key":"5023_CR39","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","volume":"4","author":"C Visco","year":"2017","unstructured":"Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D et al (2017) Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol 4:e15-23","journal-title":"Lancet Haematol"},{"key":"5023_CR40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL et al (2020) Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol 189:684\u2013688","journal-title":"Br J Haematol"},{"key":"5023_CR41","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331\u20131342","journal-title":"N Engl J Med"},{"key":"5023_CR42","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA et al (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397:892\u2013901","journal-title":"Lancet"},{"key":"5023_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-134609","volume":"136","author":"PL Zinzani","year":"2020","unstructured":"Zinzani PL, Delwail V, Paneesha S, Rule S, Martin Garcia-Sancho A, Marin-Niebla A et al (2020) Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma previously treated with ibrutinib (CITADEL-205). Blood 136:43\u201344","journal-title":"Blood"},{"key":"5023_CR44","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1200\/JCO.2021.39.15_suppl.7519","volume":"39","author":"C Carlo-Stella","year":"2021","unstructured":"Carlo-Stella C, Hutchings M, Offner FC, Morschhauser F, Bachy E, Crump M et al (2021) Glofitamab step-up dosing (SUD): complete response rates in updated efficacy data in heavily pretreated relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL) patients (pts). JCO 39:7519\u20137519","journal-title":"JCO"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05023-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T04:22:38Z","timestamp":1672719758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05023-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5023"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05023-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}